drugset
Drugs / Cell-Derived Trivalent Subunit Influenza Vaccine
last change Jan 2011 re-read 3 minutes ago

Cell-Derived Trivalent Subunit Influenza Vaccine

also known as CCIV · cTIV

Vaccine

Developed for
influenza
Investigated by
Abbott Biologicals · Novartis Vaccines · Quintiles, Inc.

Trials 2

today NCT00889889 · Ph 2 NCT00310804 · Ph 3
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00889889 May 2009 → Jan 2011 influenza Abbott Biologicals Completed No outcome recorded
Phase 31 trial · 1 met primary
Phase 3 NCT00310804 Sep → Oct 2005 influenza Novartis Vaccines Completed Met primary

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Cell-Derived Trivalent Subunit Influenza Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00310804 ↗
1

NCT00889889 ↗
Known as CCIV “cell-culture-derived influenza vaccine (CCIV)” PMID 19666152 ↗ Aug 2009
Known as cTIV “Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)” NCT00310804 ↗
Modality Vaccine “cell-derived subunit influenza vaccine” NCT00310804 ↗
Route Intramuscular “intramuscular injection” NCT00310804 ↗